Outcomes of patients with relapsed or refractory classic Hodgkin lymphoma after frontline brentuximab vedotin
Open Access
- 25 June 2026
- journal article
- Published by Springer Nature in Blood Cancer Journal
- Vol. 16 (1)
Abstract
Frontline therapy for classic Hodgkin Lymphoma (cHL) incorporating brentuximab vedotin (BV) improves outcomes compared with traditional chemotherapy, but up to 20% of patients relapse and need salvage treatment. Prior retrospective studies examining salvage therapies are mostly limited to patients who received chemotherapy-based treatment in frontline without novel agents. We evaluated outcomes in 116 patients with relapsed/refractory (R/R) cHL who received brentuximab and anthracycline-containing frontline treatment. High risk factors at relapse or progression were common, including primary refractory disease (62%), advanced stage (63%), and extranodal disease (46%). At first salvage, 73% of patients received PD-1 blockade (58% in conjunction with chemotherapy), and 81% received PD-1 blockade at any salvage line. Overall, 78% of patients proceeded to ASCT. With a median follow-up of 19 months, the 2-year PFS and OS from the start of salvage in all patients were 61% and 97% respectively. Among patients with ASCT, the 2-year post-transplant PFS (PFSHCT) was 76% for patients who had PD-1 blockade as salvage before ASCT, compared with 59% for those who did not. In univariate analysis, PD-1 blockade use in first salvage was significantly associated with improved PFSHCT, and this association remained statistically significant after adjusting for stage, extranodal involvement, and primary refractory disease (HR 0.31, p = 0.04). Primary refractory disease after BV-AVD emerged as an ongoing unmet need with a significantly inferior 2-year PFSHCT compared with relapsed patients (58% vs 86%, p = 0.017). Among primary refractory patients who received ASCT, first salvage incorporating a PD-1 blockade showed a trend toward improved PFSHCT compared with non-PD-1 blockade salvage. These results support PD-1 blockade incorporation as preferred first salvage in R/R cHL after BV-containing frontline therapy.Keywords
This publication has 26 references indexed in Scilit:
- Nivolumab plus ifosfamide, carboplatin, and etoposide are a highly effective first salvage regimen in high‐risk relapsed/refractory Hodgkin lymphomaHemaSphere, 2025
- Pembrolizumab Added to Ifosfamide, Carboplatin, and Etoposide Chemotherapy for Relapsed or Refractory Classic Hodgkin LymphomaJAMA Oncology, 2023
- Checkpoint inhibitor‐based salvage regimens prior to autologous stem cell transplant improve event‐free survival in relapsed/refractory classic Hodgkin lymphomaAmerican Journal of Hematology, 2023
- Immune-checkpoint inhibitor use in patients with cancer and pre-existing autoimmune diseasesNature Reviews Rheumatology, 2022
- Overall Survival with Brentuximab Vedotin in Stage III or IV Hodgkin’s LymphomaNew England Journal of Medicine, 2022
- Autologous stem-cell transplantation after second-line brentuximab vedotin in relapsed or refractory Hodgkin lymphomaAnnals of Oncology, 2017
- PET-adapted sequential salvage therapy with brentuximab vedotin followed by augmented ifosamide, carboplatin, and etoposide for patients with relapsed and refractory Hodgkin's lymphoma: a non-randomised, open-label, single-centre, phase 2 studyThe Lancet Oncology, 2015
- ESHAP as salvage therapy for relapsed or refractory Hodgkin’s lymphomaAnnals of Hematology, 2014
- Gemcitabine, vinorelbine, and pegylated liposomal doxorubicin (GVD), a salvage regimen in relapsed Hodgkin's lymphoma: CALGB 59804Annals of Oncology, 2007
- Time-intensified dexamethasone/cisplatin/cytarabine:an effective salvage therapy with low toxicity in patients with relapsed and refractory Hodgkin’s diseaseAnnals of Oncology, 2002